Understanding how PD-1 affects B cells in breast cancer
Official title: Function of PD-1 Signaling on the Activity of B cells in the Tumor Microenvironment in Breast Cancer
Funded at Univ of North Carolina Chapel Hill · NIH-10995813 · Data updated 2026-11-12
This study is looking at how a specific protein called PD-1 affects B cells in breast cancer, especially the harder-to-treat triple negative type, to find ways to make immune therapies work better for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | July 10, 2024 |
| Project end | July 9, 2027 |
| Funding year | 2024 |
| Award (this year) | $47,153 |
| NIH project number | 1F31CA288161-01A1 |
| Project ID | NIH-10995813 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are considering or undergoing immune checkpoint inhibitor therapy.
✕Less likely to help
Patients with non-breast cancer types or those not eligible for immune checkpoint inhibitor therapies may not benefit from this research.
What this research studies
This research investigates the role of PD-1 signaling in B cells within the tumor microenvironment of breast cancer, particularly focusing on triple negative breast cancer. The study aims to explore how PD-1 influences B cell behavior and metabolism, which may impact the effectiveness of immune checkpoint inhibitor therapies. By examining the interactions between B cells and other immune cells, the research seeks to uncover mechanisms that could enhance treatment outcomes for patients. The findings could lead to improved strategies for utilizing PD-1-targeted therapies in breast cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple negative breast cancer by improving the efficacy of immune therapies.
How similar studies have gone: Previous research has shown promising results in understanding immune checkpoint inhibitors, but the specific focus on PD-1 signaling in B cells within breast cancer is relatively novel.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Pan, Xiaolu — Univ of North Carolina Chapel Hill
- Study coordinator: Pan, Xiaolu
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.